FORMAC appoints new CEO

01-Dec-2009 - Belgium

FORMAC Pharmaceuticals N.V. announced that as of January 1, 2010 Jan Rosier will become the company’s new Chief Executive Officer (CEO), replacing Laurens G. Theunis. The change in management takes place at a time where FORMAC is moving its lead program FP-0110 into Phase IIa clinical development.

Jan Rosier joins FORMAC from Johnson & Johnson where he was Vice President Infectious Diseases ChemPharm Development. At Johnson & Johnson he was instrumental to many successes of the TIBOTEC portfolio including the development and approval of PREZISTA and INTELENCE in HIV, the progress of telaprevir (VX-950) and TMC435 in hepatitis C and of TMC207 in tuberculosis.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances